The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive cellular therapy to treat cancer by modulating the immune response have led to unprecedented responses in patients with advanced-stage tumours that would otherwise have been fatal. To date, three immune-checkpoint-blocking mAbs have been approved in the USA for the treatment of patients with several types of cancer, and more patients will benefit from immunomodulatory mAb therapy in the months and years ahead. Concurrently, the adoptive transfer of genetically modified lymphocytes to treat patients with haematological malignancies has yielded dramatic results, and we anticipate that this approach will rapidly become the standard of care for an increasing number of patients. In this Review, we highlight the latest advances in immunotherapy and discuss the role that it will have in the future of cancer treatment, including settings for which testing combination strategies and 'armoured' CAR T cells are recommended.

[1]  W. Coley.  The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). , 1910, Proceedings of the Royal Society of Medicine.

[2]  F. Welch,et al.  Causes and Consequences , 2017, Nature.

[3]  I. Fidler,et al.  Biological diversity in metastatic neoplasms: origins and implications. , 1982, Science.

[4]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Yoshida,et al.  The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.

[6]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[7]  D. Bruniquel,et al.  CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins , 1995, European journal of immunology.

[8]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[9]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[10]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[11]  A. Aruffo,et al.  4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses , 1997, The Journal of experimental medicine.

[12]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[13]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[14]  N Tsukada,et al.  Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.

[15]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[16]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[17]  J. Banchereau,et al.  CD40‐CD40 ligand , 2000, Journal of leukocyte biology.

[18]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[19]  P. Rogers,et al.  OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. , 2001, Immunity.

[20]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[21]  Sujung Park,et al.  4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11 , 2002, The Journal of Immunology.

[22]  M. Meseck,et al.  OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[24]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[25]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[26]  A. Sharpe,et al.  Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation , 2002, European journal of immunology.

[27]  M. Croft.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? , 2003, Nature Reviews Immunology.

[28]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[30]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[31]  J. Wolchok,et al.  CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. , 2004, Vaccine.

[32]  金丸 史子.  Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25[+] regulatory CD4[+] T cells , 2004 .

[33]  L. Young,et al.  The role of the CD40 pathway in the pathogenesis and treatment of cancer. , 2004, Current opinion in pharmacology.

[34]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[35]  H. Simon,et al.  Functional expression of CD134 by neutrophils , 2004, European journal of immunology.

[36]  Lieping Chen,et al.  Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.

[37]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[38]  P. Gaulard,et al.  Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand , 2004, Immunogenetics.

[39]  R. Aspinall,et al.  Thymic Involution in Aging , 2000, Journal of Clinical Immunology.

[40]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[41]  M. Colombo,et al.  Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. , 2005, Blood.

[42]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[43]  B. Dörken,et al.  Costimulation by CD137/4–1BB inhibits T cell apoptosis and induces Bcl‐xL and c‐FLIPshort via phosphatidylinositol 3‐kinase and AKT/protein kinase B , 2005, European journal of immunology.

[44]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[45]  W. Shi,et al.  Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. , 2006, Anticancer research.

[46]  R. Larson,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  M. Smyth,et al.  Eradication of established tumors in mice by a combination antibody-based therapy , 2006, Nature Medicine.

[48]  M. Devidas,et al.  Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. , 2005, Blood.

[49]  H. Heslop,et al.  The clinical use of LMP2-specific cytotoxic T lymphocytes for the treatment of relapsed EBV +ve Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) , 2006 .

[50]  K. Hacène,et al.  A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. , 2006, Cancer letters.

[51]  S. Quezada,et al.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.

[52]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[53]  S. Rosenberg,et al.  Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis , 2007, Journal of immunotherapy.

[54]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[55]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[56]  C. Riccardi,et al.  Glucocorticoid-Induced TNFR-Related Protein Lowers the Threshold of CD28 Costimulation in CD8+ T Cells1 , 2007, The Journal of Immunology.

[57]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[58]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[59]  F. Appelbaum,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[60]  S. Rosenberg,et al.  Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. , 2008, Human gene therapy.

[61]  L. Siu,et al.  First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting , 2008, Journal of hematology & oncology.

[62]  J. Wolchok,et al.  OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis , 2009, The Journal of experimental medicine.

[63]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[64]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[65]  K. Takeda,et al.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. , 2009, Blood.

[66]  S. Sakaguchi,et al.  CD4+CD25−LAG3+ regulatory T cells controlled by the transcription factor Egr-2 , 2009, Proceedings of the National Academy of Sciences.

[67]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[68]  B. Escudier,et al.  A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[69]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[70]  F. Powrie,et al.  OX40 is required for regulatory T cell–mediated control of colitis , 2010, The Journal of experimental medicine.

[71]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[72]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[73]  Thomas M. Schmitt,et al.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.

[74]  S. Anand,et al.  B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. , 2010, Blood.

[75]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[76]  J de Lange,et al.  An evidence-based review? , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[77]  J. Wolchok,et al.  Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation , 2010, PloS one.

[78]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[79]  J. Allison,et al.  Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance , 2010, Proceedings of the National Academy of Sciences.

[80]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[81]  J. Wolchok,et al.  Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. , 2010, Current opinion in investigational drugs.

[82]  J. Allison,et al.  Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals , 2010, Clinical Cancer Research.

[83]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[84]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[85]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[86]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[87]  J. Allison,et al.  Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production , 2011, PloS one.

[88]  K. Garber.  Beyond ipilimumab: new approaches target the immunological synapse. , 2011, Journal of the National Cancer Institute.

[89]  G. Freeman,et al.  The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo , 2011, The Journal of Immunology.

[90]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[91]  Jeffrey T. Lau,et al.  CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma , 2011, Science Translational Medicine.

[92]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[93]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[94]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[95]  J. Timmer,et al.  Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. , 2011, Blood.

[96]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[97]  S. Deaglio,et al.  Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. , 2011, Leukemia research.

[98]  M. Smyth,et al.  Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. , 2011, Cancer research.

[99]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[100]  F. Marincola,et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.

[101]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[102]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[103]  J. Allison,et al.  CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection , 2012, Oncoimmunology.

[104]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[105]  C. Weyand,et al.  Signaling pathways in aged T cells - a reflection of T cell differentiation, cell senescence and host environment. , 2012, Seminars in immunology.

[106]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[108]  D. Hafler,et al.  The TIGIT/CD226 Axis Regulates Human T Cell Function , 2012, The Journal of Immunology.

[109]  M. Sadelain,et al.  Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL , 2012 .

[110]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[111]  H. Abken,et al.  OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells , 2012, Oncoimmunology.

[112]  H. Yoshiyama,et al.  Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 , 2012, Nature Immunology.

[113]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[114]  P. Klenerman.  Faculty Opinions recommendation of Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. , 2012 .

[115]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[116]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[117]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[118]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[119]  H. Asaoku,et al.  T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells , 2011, Leukemia.

[120]  M. Smyth,et al.  Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells , 2013, Clinical Cancer Research.

[121]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[122]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[123]  K. Campbell,et al.  Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells , 2013, Front. Immunol..

[124]  Angel F. Lopez,et al.  Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD123‐specific chimeric antigen receptor , 2013, British journal of haematology.

[125]  H. Heslop,et al.  Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target κ-Light Immunoglobulin Chain , 2013 .

[126]  C. Cohen,et al.  Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity , 2013, The Journal of Immunology.

[127]  S. Rosenberg,et al.  Collapse of the tumor stroma is triggered by IL-12 induction of Fas. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[128]  I. Salmon,et al.  Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma , 2013, Journal of immunotherapy.

[129]  S. Grupp,et al.  Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL , 2013 .

[130]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[131]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[132]  J. Wolchok,et al.  GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability , 2013, Cancer Immunology Research.

[133]  J. Gribben,et al.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.

[134]  G. Dranoff,et al.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies , 2013, The Journal of experimental medicine.

[135]  B. Fox,et al.  OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.

[136]  A. Korman,et al.  Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.

[137]  M. Raffeld,et al.  B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma , 2013, Clinical Cancer Research.

[138]  Xiuli Wang,et al.  T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.

[139]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[140]  I. Pastan,et al.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. , 2013, Blood.

[141]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[142]  S. Grupp,et al.  Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells , 2014 .

[143]  M. Caligiuri,et al.  CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma , 2013, Leukemia.

[144]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[145]  P. Oefner,et al.  CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. , 2014, Blood.

[146]  V. Kuchroo,et al.  Mechanisms of TIGIT-driven immune suppression in cancer , 2014, Journal of Immunotherapy for Cancer.

[147]  M. Sadelain,et al.  CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL , 2014 .

[148]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[149]  S. Riddell,et al.  Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.

[150]  D. Dolfi,et al.  Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors , 2014, Clinical Cancer Research.

[151]  P. Parren,et al.  CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma , 2014 .

[152]  C. Ziegler,et al.  Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes , 2014, Cancer Immunology Research.

[153]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[154]  M. Carroll,et al.  Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. , 2014, Blood.

[155]  M. Sadelain,et al.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity , 2014, Science Translational Medicine.

[156]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[157]  D. Teachey,et al.  T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL , 2014 .

[158]  J. Wolchok,et al.  Immune modulation for cancer therapy , 2014, British Journal of Cancer.

[159]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[160]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[161]  Matthew J. Frigault,et al.  ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. , 2014, Blood.

[162]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[163]  B. Kwon,et al.  4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy , 2014, BMB reports.

[164]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[165]  David C. Smith,et al.  Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. , 2014 .

[166]  S. Grupp,et al.  Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma , 2014, Cancer Immunology Research.

[167]  H. Kantarjian,et al.  Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor , 2014 .

[168]  H. Kohrt,et al.  Targeting CD137 enhances the efficacy of cetuximab. , 2014, The Journal of clinical investigation.

[169]  S. Giralt,et al.  IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia , 2014, Leukemia.

[170]  D. Porter,et al.  Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. , 2015 .

[171]  M. Morgan,et al.  Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers , 2015 .

[172]  M. Carroll,et al.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia , 2015, Leukemia.

[173]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[174]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[175]  K. Curran,et al.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[176]  J. Wolchok,et al.  Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 , 2015, Cell Research.

[177]  L. Ysebaert,et al.  Nurse like cells: chronic lymphocytic leukemia associated macrophages , 2015, Leukemia & lymphoma.

[178]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[179]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  Milton L. Greenberg,et al.  Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming , 2015, Nature Communications.

[181]  S. Heimfeld,et al.  Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. , 2015 .

[182]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[184]  M. Curran,et al.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity , 2015, Front. Oncol..

[185]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[186]  Hidde L. Ploegh,et al.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion , 2014, Nature.

[187]  J. Gribben,et al.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. , 2015, Blood.

[188]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[189]  D. Spriggs,et al.  IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo , 2015, Oncoimmunology.

[190]  M. Sadelain,et al.  Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. , 2015 .

[191]  Na Li,et al.  Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.

[192]  D. Torigian,et al.  Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. , 2015 .

[193]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[194]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[195]  J. Wolchok,et al.  The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. , 2015, Advances in cancer research.

[196]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[197]  R. Brentjens,et al.  CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? , 2015, Immunotherapy.

[198]  J. Taube,et al.  Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting , 2015, Journal of Translational Medicine.

[199]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[200]  S. Endres,et al.  Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. , 2015, Journal of the National Cancer Institute.

[201]  J. Wolchok,et al.  Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. , 2015, The New England journal of medicine.

[202]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[203]  M. Sadelain,et al.  Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). , 2015 .

[204]  J. Ravetch,et al.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.

[205]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[206]  M. Sadelain,et al.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.

[207]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[208]  Lung-Ji Chang,et al.  415. First-In-Patient Proof of Safety and Efficacy of a 4th Generation Chimeric Antigen Receptor-Modified T Cells for the Treatment of Relapsed or Refractory CD30 Positive Lymphomas , 2015 .

[209]  D. Spriggs,et al.  A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer , 2015, Journal of Translational Medicine.

[210]  J. Brown,et al.  Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. , 2016, Neuro-oncology.

[211]  Renier J. Brentjens,et al.  Driving CAR T-cells forward , 2016, Nature Reviews Clinical Oncology.

[212]  C. Croce,et al.  The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells , 2015, Leukemia.

[213]  W. Han,et al.  CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma , 2016 .

[214]  Susan O'Brien,et al.  Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. , 2018, The Lancet. Haematology.